Table 3.
Description of methylation status by methylation-specific PCR (MSP) in relation to main demographic and clinical parameters
| MGMT Methylation (%) | RASSF1 methylation (%) | CDKN2A methylation (%) | |
|---|---|---|---|
| Gender | |||
| Male | 14/56 (25.0%) | 4/44 (9.1%) | 5/40 (12.5%) |
| Female | 12/32 (37.5%) | 4/22 (18.2%) | 2/21 (9.5%) |
| Smoking status | |||
| Never smoker | 5/11 (45.5%) | 0/9 (0.0%) | 2/8 (25.0%) |
| Ever smoker | 21/77 (27.3%) | 8/57 (14.0%) | 5/53 (9.4%) |
| Alcohol use | |||
| Never drinker | 4/16 (25.0%) | 0/12 (0.0%) | 4/12 (33.3%)* |
| Ever drinker | 22/72 (30.6%) | 8/54 (14.8%) | 3/49 (6.1%)* |
| Family history | |||
| Negative | 11/41 (26.8%) | 3/35 (8.6%) | 4/30 (13.3%) |
| Positive | 15/47 (31.9%) | 5/31 (16.1%) | 3/31 (9.7%) |
| Histology | |||
| Squamous | 24/85 (28.2%) | 8/65 (12.3%) | 7/60 (11.7%) |
| Other | 2/3 (66.7%) | 0/1 (0.0%) | 0/1 (0.0%) |
| Anatomic site | |||
| Oral cavity & lip | 12/50 (24.0%) | 5/37 (13.5%) | 6/35 (17.1%) |
| Oropharynx | 14/38 (36.8%) | 3/29 (10.3%) | 1/26 (3.8%) |
| Stage at diagnosis | |||
| Local (I, II) | 11/36 (30.6%) | 5/27 (18.5%) | 4/26 (15.4%)* |
| Advanced (III, IV) | 15/52 (28.8%) | 3/39 (7.7%) | 3/35 (8.6%)* |
| Treatment | |||
| Surgery only | 9/44 (20.5%) | 3/26 (11.5%) | 3/24 (12.5%) |
| Surgery and radiotherapy | 16/39 (41.0%) | 5/40 (12.5%) | 4/37 (10.8%) |
| Surgery and chemoradiation | 1/5 (20.0%) | ----- | ----- |
| HPV | |||
| Negative | 18/67 (26.9%) | 7/47 (14.9%) | 7/45 (15.6%) |
| Positive | 8/21 (38.1%) | 1/19 (5.3%) | 0/7 (0.0%) |
* Statistically significant (α = 0.05)